Aakha.bio - A world-changing drug discovery engine

We are a new kind of biotech company

We value efficiency in the drug discovery process, rapidly bringing high quality therapeutics to patients. We utilize multiple advanced antibody discovery platforms to empower experienced drug hunters to go efficiently from concept to IND enabling studies.

Discovering medicine is in our DNA. Our team has discovered drugs that are being used to treat patients today.

Our synergistic approach reduces the time required to optimize, develop, and produce world-class therapeutic options.

Our complementary discovery and business models are designed to support the scientists who create therapies that save lives.

Meet The Team

Our team pairs drug discovery and financial strategists for an innovative biotechnology startup model that puts scientists and patients first.

Hemanta Baruah

Founder & CEO

An experienced drug developer with an approved checkpoint inhibitor and several additional candidates in advanced clinical trials.

Errik Anderson

Board Member

Founder and CEO of Alloy Therapeutics. Serial biotech scientist entrepreneur including co-founding Adimab, Alector, Arsanis, Avitide, and Compass Therapeutics.

Chris Pacheco, PhD

Board Member

Executive Partner at 82VS, Alloy Therapeutics’ affiliated venture studio. Formerly, Chris was at Polaris Partners, Roche Diagnostics, and the Whitehead Institute.

Robert Mabry, PhD

Board Member

CSO at Orna Therapeutics. Formerly, Robert was at Takeda Pharmaceuticals, Cogen Therapeutics (Repertoire Immune Medicines), Jounce Therapeutics, and Adimab.

Manoj Sabnani

Scientist

Associate scientist at Alloy Therapeutics, previously lab coordinator at University of Texas Arlington and researcher at Texas Tech University Health Sciences Center and Purdue University Calumet.

Rajeev Shrimali, PhD

Director of Immunology

Expertise in advancing targeted, immune therapeutics and their combinations for oncology and inflammation indications with several candidates in advanced clinical trials & one approved drug.

News & Media

May 22, 2024

Aakha Biologics Received a Combined Total of $2.95 Million Non-Dilutive Funding from CPRIT and NCI to Accelerate IND-enabling Studies for Next-Generation Immunotherapies for the Treatment of Advanced Non-Small Cell Lung Cancer

A Special Partnership

Incubated in Alloy Therapeutics’ affiliated venture studio, Aakha.bio was created through a collaborative partnership model that leverages access to Alloy’s ATX-Gx™ transgenic mouse, suite of antibody discovery platforms, and discovery services.

If you are a drug hunter looking to join a focused and energized team, please connect with us

[email protected]